Table 1.
Data corresponding to enrolled subjects per study group.
| Subject ID | Sex | Age (years) | Time of exposurea (years) | Plasma viral load (VL)b |
CD4 + T cell countc (cells/μl) | HLA |
Viral subtyped | ||
|---|---|---|---|---|---|---|---|---|---|
| (HIV RNA copies/ml) | Log10 (copies/ml) | A | B | ||||||
| Group SDC: serodiscordant couples (N = 9)e | |||||||||
| HIV+-P1 | F | 45 | 6 | 36,364 | 4.56 | 530 | 02/25 | 8/51 | BF |
| ESN1 | M | 40 | < 50 | < 1.7 | 1208 | 02/29 | 44CXHZ/7 | − | |
| HIV+-P2 | M | 47 | 10 | 95,821 | 4.98 | 41 | 02/08 | 48/35 | BF |
| ESN2 | F | 43 | < 50 | < 1.7 | 634 | 01/32 | 44CXJC/18 | − | |
| HIV+-P3 | M | 37 | 3 | 21,758 | 4.33 | 370 | NA | NA | C |
| ESN3 | F | 32 | < 50 | < 1.7 | 904 | 02/34 | 40CXJJ (61)/14 | − | |
| HIV+-P4 | F | 33 | 5 | 177 | 2.24 | 386 | 11/68 | 35/08 | NA |
| ESN4 | M | 26 | < 50 | < 1.7 | 850 | 02/24 | 15CXHX (62)/07 | − | |
| HIV+-P5 | M | 34 | 5–7 | 901 | 2.9 | 160 | 02/02 | 39/39 | NA |
| ESN5 | F | 73 | < 50 | < 1.7 | 672 | 01/02 | 8/44CXJC | − | |
| HIV+-P6 | M | 30 | 10 | 364,928 | 5.56 | 21 | NA | NA | BF |
| ESN6 | F | 31 | < 50 | < 1.7 | 713 | NA | NA | − | |
| HIV+-P7 | M | 41 | 5 | 15,867 | 4.2 | 333 | 68/36 | 07/44CXJC | BF |
| ESN7 | F | 43 | < 50 | < 1.7 | 606 | 02/11 | 07/38 | − | |
| HIV+-P8 | M | 40 | > 3 | 81 | 1.9 | 259 | 2/24 | 25/29 | NA |
| ESN8 | F | 25 | < 50 | < 1.7 | 1214 | 40/35 | 50/36 | − | |
| HIV+-P9 | F | 36 | > 3 | 465 | 3.05 | 256 | 01/33 | 45/52 | NA |
| ESN9 | M | 26 | < 50 | < 1.7 | 497 | 32/32 | 8/38 | − | |
| Group C: chronics (N = 18) | |||||||||
| C01 | F | 21 | − | 85,947 | 4.9 | 25 | 11/24 | 35/51or78f | BF |
| C02 | M | 22 | − | 18,580 | 4.2 | 511 | 1/3 | 7/37 | B |
| C03 | M | 49 | − | 43,436 | 4.6 | 479 | 31/31 | 15/39 | |
| C04 | M | 28 | − | 555 | 2.7 | 555 | 2/3 | 44/51 | BF |
| C05 | M | 36 | − | 1288 | 3.1 | 431 | NA/NA | NA/NA | C |
| C06 | F | 27 | − | 1817 | 3.2 | 689 | 11/11 | 35/40 | |
| C07 | M | 47 | − | 11,026 | 4.0 | 585 | 2/2 | 44/28 | |
| C08 | F | 38 | − | 22,475 | 4.3 | 143 | 2/2or25f | 35/55 | B |
| C09 | F | 29 | − | 14,784 | 4.3 | 139 | 26/26 | 44/57 | BF |
| C10 | F | 24 | − | 253,167 | 5.4 | 5 | 31/31 | 39/47 | BF |
| C11 | M | 23 | − | 45,199 | 4.7 | 282 | 11/11 | 18/35 | |
| C12 | F | 50 | − | 3093 | 3.5 | 227 | 2/33 | 15/39 | |
| C13 | F | 24 | − | 1286 | 3.1 | 1071 | 2/3 | 35/44 | BF |
| C14 | M | 26 | − | 22,060 | 4.3 | 293 | 2/2 | 7/35 | BF |
| C15 | M | 33 | − | 4698 | 3.7 | 408 | 31/31 | 8/48 | BF |
| C16 | M | 40 | − | 25,402 | 4,4 | 692 | 2/36 | 7/42 | B |
| C17 | M | 73 | − | 58,410 | 4,8 | 575 | 2/2 | 39/52 | B |
| C18 | M | 47 | − | 710 | 2,9 | 678 | 31/68 | 44/51 | BF |
| Group CT: chronics with documented transmission event (N = 9) | |||||||||
| CT01 | M | 39 | − | 25,599 | 4.4 | 223 | 31/X | 1508 (75)/35 | B |
| CT02 | M | 29 | − | 50,563 | 4.7 | 269 | 32/26 | 38BHS/44CXHZ | F |
| CT03 | M | 38 | − | 383,841 | 5.5 | 8 | 2/68 | 7CXPJ/15CXHW | B |
| CT04 | F | 40 | − | 25,899 | 4.4 | 352 | 2/24 | 15YCK/1517 | BF |
| CT05 | F | 29 | − | 1904 | 3.2 | 357 | NA/NA | NA/NA | BFC |
| CT06 | M | 30 | − | 264,322 | 5.4 | 227 | 11/3001 | 18/35 | BF |
| CT07 | M | 32 | − | 30,020 | 4.4 | 238 | NA/NA | NA/NA | BF |
| CT08 | M | 28 | − | 7666 | 3.8 | 294 | NA/NA | NA/NA | B |
| CT09 | M | 33 | − | 19,250 | 4.2 | 495 | NA/NA | NA/NA | BF |
F: Female, M: Male. NA; Not available.
a
Estimated time based on self-reported data on clinical questionnaire.
b
Versant HIV-1 RNA 3.0 assay, Siemens. Lower and upper detection limits was 50 and 500,000 RNA copies/ml, respectively (1.7 and 5.7 log10).
c
Flow cytometry double platform, FACSCanto, BD Biosciences.
d
Viral subtype determined by pol gene sequencing.
e
Both individuals belonging to one couple are shown in side by side lines and are indicated with the same number. HIV+-P: HIV Positive Partner, ESN: Exposed seronegative subject.
f
Could not be exactly determined.